Cabozantinib is a first-generation therapeutic targeted drug

Cabometinib, also known asXL184 or Cometriq/Cabometyx (depending on its dosage form), is a third-generation targeted drug widely used in tumor treatment. As a small molecule multi-target tyrosine kinase inhibitor, cabozantinib has shown unique advantages in the field of cancer treatment.

Compared with traditional targeted drugs, cabozantinib has a broader inhibitory spectrum and higher anti-tumor activity. It can simultaneously act on multiple targets closely related to tumor growth, angiogenesis and metastasis, including but not limited to MET, VEGFR (including VEGFR1, VEGFR2, VEGFR3), ROS1, RET, AXL, NTRK and KIT, etc. This multi-target inhibitory effect makes cabozantinib outstanding in the treatment of multiple cancer types, including medullary thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.

It is worth noting that different dosage forms of cabozantinib have different approved therapeutic indications. For example, the capsule form of cabozantinib (Cometriq) is mainly used to treat medullary thyroid cancer, while the tablet form of cabozantinib (Cabometyx) is used to treat renal cell carcinoma, hepatocellular carcinoma and certain types of differentiated thyroid cancer. This difference in dosage form reflects the flexibility and specificity of cabozantinib in the treatment of different cancer types.

In clinical practice, cabozantinib has demonstrated significant therapeutic effects, providing patients with new treatment options and hope. However, as a powerful targeted drug, cabozantinib may also cause some side effects, such as diarrhea, fatigue, hypertension, and hand-foot syndrome. Therefore, when using cabozantinib, doctors will develop an individualized treatment plan based on the patient's specific situation and closely monitor the patient's response and side effects to ensure the safety and effectiveness of the treatment.

In summary, cabozantinib, as a third-generation targeted drug, has broad application potential and important clinical value in the field of tumor treatment.